<h2>Treatment opportunities and challenges</h2>
The risks associated with T2D, especially cardiovascular (CV) complications, stress the importance of early intervention.1,2&nbsp;Newer medications like SGLT2 inhibitors and GLP-1 receptor agonists offer promising results, not just for glucose control but also regarding CV and renal benefits.3,4&nbsp;However, therapeutic inertia and the complexity of the disease pose significant challenges which accentuate the need for better follow-up, treatment strategies and personalized care.5

<h3>Key takeaways on treatment opportunities and challenges</h3>
<ul>
 <li>T2D is a complex disease with a high CV risk and progressive beta-cell failure 
 <ul>
 <li>Early multifactorial intervention is key 
 &nbsp;</li>
 </ul></li>
 <li>There is an enormous improvement in treatment options, although there is a disconnection between evidence/guidelines and clinical practice as well as major clinical inertia 
 &nbsp;</li>
 <li>Improvement of healthcare professional (HCP) skills, knowledge and organisation is needed</li>
</ul>

<h2>Personalized medicine in diabetes management</h2>
T2D significantly impacts patient health outcomes, particularly in relation to CV risk and loss of life expectancy, which can be 14-16 years and is largely influenced by the age at diagnosis.6&nbsp;Research indicates that common risk factors, such as elevated cholesterol and blood pressure further exacerbate mortality risks, potentially doubling or tripling the likelihood of CV death.7&nbsp;“Hypoglycemia by itself is an independent risk factor for CV disease”, Prof. De Galan stated. Interestingly, while controlling hyperglycemia is critical, intensive glucose-lowering treatments have shown a neutral effect on CV outcomes.8&nbsp;A holistic and personalized approach is essential to effectively manage diabetes, addressing multiple health aspects such as glucose control, weight management, and CV risk factors.9&nbsp;New medications such as SGLT2 inhibitors and GLP-1 receptor agonists, have emerged as valuable tools in reducing CV risk, with the former notably improving renal function and heart failure (HF) outcomes.3,4

<h3>Key takeaways on personalized medicine in diabetes management</h3>
<ul>
 <li>Management of T2D requires a personalized approach targeting multiple components 
 &nbsp;</li>
 <li>GLP-1 receptor agonists and SGLT2-inhibitors independently improve CV and renal outcomes in T2D 
 &nbsp;</li>
 <li>Use of GLP-1 receptor agonists and SGLT2-inhibitors increases among in-patients without T2D 
 &nbsp;</li>
 <li>Stopping SGLT2-inhibitors prior to surgery may not be necessary, but specific action may be required (e.g., insulin/glucose drip)</li>
</ul>

Curious about pharmacologic aspects of personalized T2D medicine according to Prof. De Galan? You can watch the session in video below.
<h2>Deep dive in subpopulations</h2>
Prof. Eliasson highlighted the complexity of T2D management, particularly the concept of clustering patients based on their characteristics. In 2018, it was assessed whether distinct clusters of diabetes subpopulations could be formed using computational methods. Although clustering was found to be feasible, it lacked clinical utility because there was no evidence supporting a fixed number of clusters.10&nbsp;The findings suggest that while patients can be categorized into various groups based on factors like HbA1c levels and insulin secretion, the variations within these clusters were significant, making it challenging to draw meaningful conclusions.10,11&nbsp;“Accurate diagnosis is therefore highly important, especially in atypical cases where patients may not fit the traditional profiles of T1D or T2D”, Prof. Eliasson said. Management strategies for diabetes must consider individual patient history and characteristics, including the presence of other comorbidities. According to the guidelines, SGLT2-inhibitors and GLP-1 receptor agonists are suitable for a large number of subpopulations.9
<h3>Learn what Prof. Eliasson has to say on managing subpopulations in the video below.</h3>

<h3>Key takeaways on subpopulations</h3>
<ul>
 <li>Individualize and tailor treatment 
 &nbsp;</li>
 <li>Pay attention to the treatment recommendations (EASD/ADA and ESC) as these are good</li>
</ul>

The Sanofi webinar ‘Act Now for Impact: Glycemic Control and Beyond’ focuses on recent advancements in treating type 2 diabetes (T2D), emphasizing a personalized approach for better outcomes. Prof. Frank Nobels (Belgium), prof. De Galan (the Netherlands) and Prof Björn Eliasson (Sweden) addressed various aspects of T2D treatment in the present era.

TYPE-2-DIABETES

DIABETES

Personalized approach in T2D is key for success

<h3>Don't miss this insightful discussion on tailoring care to individual need in the pursuit for a better glycemic control for T2D. Watch the 15 min discussion here:</h3>

Heeft u vragen of wilt u meer weten? Wij zorgen dat u zo snel mogelijk geholpen wordt.

Wij staan klaar

Voor uw intercontext, meld u aan bij uw account Sanofi Campus. Geef uw e-mail door aan uw e-mail.

Als u onze eerste e-mail op {email} tot bevestig uw account u kunt hieronder een nieuwe aanvragen. Als je het niet ziet, moet je mogelijk je spammap controleren.

Deze informatie wordt alleen gebruikt om uw account te valideren en wordt niet verspreid.

titel

Title

This website is for healthcare professionals only.

Welcome to BP Sanofi Campus

Create new password

Om u een gepersonaliseerde ervaring te bieden, moet u

Je profiel is onvolledig

De ADCT geeft een indicatie van hoe gecontroleerd het eczeem is. Beantwoord deze 6 eenvoudige vragen met uw patiënt om de ADCT-score te vinden. Het zal de juiste handelwijze aangeven.

Atopische dermatitis, een vorm van eczeem, kan het leven van uw patiënt op meer manieren beïnvloeden dan u weet.

Doe de atopische dermatitis controle test (ADCT)

Geniet van meer exclusieve inhoud{newline}door <a>door u vandaag te registreren</a>

Heb je al een account? <a>Hier inloggen</a>

Best practices voor het optimaliseren van de patiëntenzorg

Krijg een aangepast beeld van de onderwerpen waarin u geïnteresseerd bent, samen met de mogelijkheid om inhoud op te slaan om op een later tijdstip te bekijken of te lezen.

Onbeperkte toegang tot eersteklas inhoud, whitepapers, casestudy's, onderzoekspapers, webinars, training en up-to-date wetenschappelijke medische bronnen.

Gepersonaliseerde inhoud op basis van uw interessegebieden

Maak contact en blijf up-to-date met collega's op uw vakgebied en onderwerpen die u interesseren via gratis evenementen en leidinggevende forums.

Registreer om het volledige artikel te lezen.

Wij respecteren uw privacy en zullen uw informatie niet delen met derden.

Actuele gidsen die speciaal voor patiënten zijn geschreven

Onbeperkte toegang tot de nieuwste patiëntengidsen en bronnen. Deel inhoud met uw patiënten met gebruiksvriendelijke online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Beperkte toegang

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

Normaal gesproken bieden we een schat aan kenis, maar we konden niet vinden waar je naar op zoek bent.

We konden niet vinden wat je zocht

Sanofi is niet verantwoordelijk voor de inhoud van deze externe website.

U staat op het punt Campus.sanofi/nl te verlaten.

Images from <a>iStockphoto.com</a>, Fotolia.de, <c>gettyimages.de</c>, <d>pexels.com</d> and <e>photocase.de</e> were used for our websites.

Volg ons:

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch. All fields are required.

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required (unless otherwise specified).

Sanofi biedt u exclusieve content over onze verschillende therapeutische gebieden op één portal speciaal voor professionals in de gezondheidszorg, inclusief wetenschappelijk nieuws, een lijst met evenementen en tools en diensten voor uw dagelijkse praktijk.

Bevestig uw status

De inhoud van deze website is alleen toegankelijk voor geregistreerde gebruikers.

Log in alstublieft

Email verificatie

U ziet een voorbeeld van de portal. Wis uw cookies (bijvoorbeeld door uw browservenster te sluiten) om terug te gaan naar de openbare modus.

We hebben onze privacyverklaring bijgewerkt om je gegevens beter te beschermen en je ervaring te verbeteren. Neem even de tijd om de wijzigingen door te nemen door <privacyNewTab>hier te klikken</privacyNewTab>. Uw privacy is belangrijk voor ons. Klik op doorgaan om te bevestigen dat u de nieuwe privacyverklaring hebt gelezen.

Update van de privacyverklaring

Communicatie toestemming

My consents

Password

Confirm password

{resultsCount, plural, one {resultaat} other {resultaten}}

Log in om toegang te krijgen tot de resultaten

U moet inloggen op uw account om toegang te krijgen tot medische inhoud.

Inloggen

Registreer in minder dan 1 minuut om toegang te krijgen tot de resultaten

U verlaat nu het Sanofi inhoudsgedeelte van onze site en komt in het inhoudsgedeelte voor extern medisch bibliografisch zoeken.

U verlaat nu het externe medische bibliografische zoekgedeelte van onze site en komt in het inhoudsgedeelte van Sanofi.